Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $242.33, for a total transaction of $484,660.00. Following the completion of the sale, the executive vice president now owns 29,815 shares of the company’s stock, valued at $7,225,068.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Marc Stapley also recently made the following trade(s):

  • On Monday, December 4th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $219.88, for a total transaction of $439,760.00.
  • On Wednesday, November 15th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $205.48, for a total transaction of $410,960.00.
  • On Thursday, October 26th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $206.88, for a total transaction of $413,760.00.

Illumina, Inc. (ILMN) traded up $2.59 during midday trading on Friday, hitting $243.90. 269,152 shares of the stock were exchanged, compared to its average volume of 1,098,233. Illumina, Inc. has a twelve month low of $156.50 and a twelve month high of $248.97. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $35,520.00, a PE ratio of 46.02, a P/E/G ratio of 3.25 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the previous year, the company posted $0.97 earnings per share. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. equities analysts forecast that Illumina, Inc. will post 3.76 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on ILMN shares. Goldman Sachs Group restated a “neutral” rating and issued a $200.00 target price on shares of Illumina in a report on Tuesday, September 26th. Piper Jaffray Companies restated an “overweight” rating and issued a $226.00 target price (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Canaccord Genuity restated a “buy” rating and issued a $230.00 target price (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. Deutsche Bank upgraded shares of Illumina from a “hold” rating to a “buy” rating and lowered their target price for the company from $195.00 to $160.00 in a report on Monday, October 23rd. Finally, Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a report on Monday, October 23rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $220.13.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Intellectus Partners LLC raised its holdings in Illumina by 6.6% in the second quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock valued at $1,871,000 after acquiring an additional 664 shares in the last quarter. Axiom International Investors LLC DE raised its holdings in shares of Illumina by 60.9% during the third quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock worth $37,142,000 after purchasing an additional 70,572 shares during the period. Virtu Financial LLC acquired a new stake in shares of Illumina during the third quarter worth $577,000. Janus Henderson Group PLC raised its holdings in shares of Illumina by 1,556.2% during the second quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock worth $57,263,000 after purchasing an additional 310,084 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Illumina by 4.9% during the third quarter. Schwab Charles Investment Management Inc. now owns 508,368 shares of the life sciences company’s stock worth $101,267,000 after purchasing an additional 23,647 shares during the period. 91.60% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Illumina, Inc. (ILMN) EVP Sells 2,000 Shares of Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/insider-selling-illumina-inc-ilmn-evp-sells-2000-shares-of-stock/1813927.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.